Abstract | BACKGROUND: METHODS: RESULTS: Forty patients received a median of four induction chemotherapy cycles. Of them, 35 (87.5%) patients received a median of nine maintenance chemotherapy cycles. The objective response was 70.6%, and the disease control rate was 97.1%. The median PFS was 10.8 (95% CI, 9.0-12.6), and overall survival was 48.0 (95% CI, 32.9-63.1) months. Median PFS of 23 patients with epidermal growth factor receptor (EGFR) mutations and of 16 patients without EGFR mutations were 12.9 (95% CI, 9.4-16.3) and 7.9 (95% CI, 1.1-14.7) months, respectively. Toxicities graded ≥3 included neutropenia (15%), anemia (15%), hypertension (7.5%), anorexia (7.5%), fatigue (7.5%), thromboembolic events (5%), jaw osteonecrosis (5%), nausea (2.5%), oral mucositis (2.5%), tumor pain (2.5%), hyponatremia (2.5%), and gastrointestinal perforation (2.5%). Treatment-related deaths were not found. CONCLUSIONS: TRIAL REGISTRATION: UMIN Clinical Trial Registry: UMIN000005569 . Registered date: May 8, 2011.
|
Authors | Yasuhiro Tsutani, Yoshihiro Miyata, Takeshi Masuda, Kazunori Fujitaka, Mihoko Doi, Yoshikazu Awaya, Shoichi Kuyama, Soichi Kitaguchi, Kazuhiro Ueda, Noboru Hattori, Morihito Okada |
Journal | BMC cancer
(BMC Cancer)
Vol. 18
Issue 1
Pg. 1231
(Dec 10 2018)
ISSN: 1471-2407 [Electronic] England |
PMID | 30526545
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Pemetrexed
- Bevacizumab
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality)
- Cisplatin
(administration & dosage)
- Female
- Humans
- Induction Chemotherapy
(methods)
- Kaplan-Meier Estimate
- Lung Neoplasms
(drug therapy, mortality)
- Maintenance Chemotherapy
(methods)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Pemetrexed
(administration & dosage)
- Progression-Free Survival
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|